Quintiles Phase One Clinical Trials India Private Limited, a dissolved (liquidated) foreign private limited company, was established on 03 July 2009 in Hyderabad, Telangana, India. Engaging in preventive health services within the healthcare sector, it holds CIN: U73100TG2009FTC064239. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹38.00 Cr and a paid-up capital of ₹36.57 Cr.
It upholds a compliant status. Its leadership includes Nilanjan Sinha (Director), Arjun Aiyar (Director), Haripprasad Kovalamuri (Director). Past directors included Paul Francis Casey, Edward Caffrey, Nilanjan Sinha. Its latest AGM occurred on 29 June 2020, with the balance sheet filed on 31 March 2020. It is based at 7Th & 8Th Floor, Apollo Health Street Building, Apollo Health City, Behind Kbr Park, Jub, Ilee Hills, Hyderabad, Telangana, 500033.
U73100TG2009FTC064239
064239
03 July 2009
₹38.00 Cr
₹36.57 Cr
Roc Hyderabad
Unlisted
Dissolved (Liquidated)
Explore comprehensive insights into Quintiles Phase One Clinical Trials India Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nilanjan Sinha | Director | 14 Nov 2016 | Current |
| Arjun Aiyar | Director | 01 Nov 2016 | Current |
| Haripprasad Kovalamuri | Director | 15 May 2013 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 17 Jun 2011 | Past |
| Pramod Abcsdd | Director | 17 Jun 2011 | Past |
| Pramod Abcsdd | Additional Director | 21 Sep 2017 | Past |
| Pramod Abcsdd | Director | 14 Nov 2016 | Past |
| Pramod Abcsdd | Alternate Director | 24 Mar 2011 | Past |
| Pramod Abcsdd | Director | 06 Jan 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Quintiles Phase One Clinical Trials India Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 95.71% decrease. The company also saw a substantial fall in profitability, with a 170.66% decrease in profit. The company's net worth observed a substantial decline by a decrease of 51.44%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2017, Quintiles Phase One Clinical Trials India had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Quintiles Phase One Clinical Trials India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Quintiles Phase One Clinical Trials India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quintiles Phase One Clinical Trials India's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Quintiles Phase One Clinical Trials India Private Limited last Annual general meeting of members was held on 29 Jun 2020 as per latest MCA records. was recorded as a recent event.
Progress on Quintiles Phase One Clinical Trials India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2020 with Roc Hyderabad. was documented.
Progress on Khusboo Singhvi was appointed as a Company Secretary was appointed as a Company Secretary on 24 Apr 2019 & has been associated with this company since 6 years 8 months . was documented.
Nilanjan Sinha was appointed as a Director was appointed as a Director on 14 Nov 2016 & has been associated with this company since 9 years 2 months . was recorded as a recent event.
Arjun Aiyar was appointed as a Director was appointed as a Director on 01 Nov 2016 & has been associated with this company since 9 years 2 months . was recorded as a recent event.
Haripprasad Kovalamuri was appointed as a Director was appointed as a Director on 15 May 2013 & has been associated with this company since 12 years 8 months . was recorded as a recent event.
The CIN of Quintiles Phase One Clinical Trials India Private Limited is U73100TG2009FTC064239.
Quintiles Phase One Clinical Trials India Private Limited is headquartered at 7Th & 8Th Floor, Apollo Health Street Building, Apollo Health City, Behind Kbr Park, Jub, Ilee Hills, Hyderabad, Telangana, 500033.
Quintiles Phase One Clinical Trials India Private Limited was incorporated on 03 July 2009.
The current directors of Quintiles Phase One Clinical Trials India Private Limited are
The primary industry of Quintiles Phase One Clinical Trials India Private Limited is Healthcare.
Quintiles Phase One Clinical Trials India Private Limited is unlisted.
The authorized capital of Quintiles Phase One Clinical Trials India Private Limited is ₹38.00 Cr, and the paid-up capital is ₹36.57 Cr.
The compliance status of Quintiles Phase One Clinical Trials India Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX